Therapy ofClostridium difficileinfection: perspectives on a changing paradigm

Clostridium difficile Infection Is Associated With Poor Outcomes in End-Stage Renal Disease

(2016) Chaitanya Pant et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Characterization of swine isolates of Clostridium difficile in Spain: A potential source of epidemic multidrug resistant strains?

(2013) Teresa Peláez et al.   ANAEROBE

In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden

(2013) Mamun-Ur Rashid et al.   ANAEROBE

Relationship Between Bacterial Strain Type, Host Biomarkers, and Mortality in Clostridium difficile Infection

(2013) A. Sarah Walker et al.   CLINICAL INFECTIOUS DISEASES

Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications

(2013) S. B. Debast et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Lack of Clostridium difficile Infection in Patients Treated With Rifaximin for Hepatic Encephalopathy

(2013) Guy W. Neff et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

A New Strategy for the Prevention of Clostridium difficile Infection

(2013) Amber Howerton et al.   JOURNAL OF INFECTIOUS DISEASES

Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile

(2013) Els van Nood et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characterization of a Stable, Metronidazole-Resistant Clostridium difficile Clinical Isolate

(2013) Tarah Lynch et al.   PLoS One

Rifaximin Resistance in Escherichia coli Associated with Inflammatory Bowel Disease Correlates with Prior Rifaximin Use, Mutations in rpoB, and Activity of Phe-Arg- -Naphthylamide-Inhibitable Efflux Pumps

(2012) V. Kothary et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

ComparativeIn VitroActivities of LFF571 against Clostridium difficile and 630 Other Intestinal Strains of Aerobic and Anaerobic Bacteria

(2012) Diane M. Citron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of LFF571 in a Hamster Model of Clostridium difficile Infection

(2012) Anna Trzasko et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study To Assess the Safety and Tolerability of LFF571 in Healthy Volunteers

(2012) Lillian S. L. Ting et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroandIn VivoCharacterization of CB-183,315, a Novel Lipopeptide Antibiotic for Treatment of Clostridium difficile

(2012) Carmela T. M. Mascio et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mechanism of Action of and Mechanism of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compound LFF571

(2012) J. A. Leeds et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial Activities of Fidaxomicin

(2012) Ellie J. C. Goldstein et al.   CLINICAL INFECTIOUS DISEASES

Fidaxomicin Is an Inhibitor of the Initiation of Bacterial RNA Synthesis

(2012) Irina Artsimovitch et al.   CLINICAL INFECTIOUS DISEASES

Decreased Cure and Increased Recurrence Rates for Clostridium difficile Infection Caused by the Epidemic C. difficile BI Strain

(2012) Laurica A. Petrella et al.   CLINICAL INFECTIOUS DISEASES

Fidaxomicin "Chaser" Regimen Following Vancomycin for Patients With Multiple Clostridium difficile Recurrences

(2012) S. Johnson et al.   CLINICAL INFECTIOUS DISEASES

Predictors of First Recurrence of Clostridium difficile Infection: Implications for Initial Management

(2012) D. W. Eyre et al.   CLINICAL INFECTIOUS DISEASES

Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model

(2012) C. H. Chilton et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Discovery of LFF571: An Investigational Agent for Clostridium difficile Infection

(2012) Matthew J. LaMarche et al.   JOURNAL OF MEDICINAL CHEMISTRY

Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial

(2012) Oliver A Cornely et al.   LANCET INFECTIOUS DISEASES

Epidemiology, risk factors, and outcomes ofClostridium difficileinfection in kidney transplant recipients

(2012) D. Neofytos et al.   Transplant Infectious Disease

Targeted Restoration of the Intestinal Microbiota with a Simple, Defined Bacteriotherapy Resolves Relapsing Clostridium difficile Disease in Mice

(2012) Trevor D. Lawley et al.   PLoS Pathogens

Diverting Loop Ileostomy and Colonic Lavage

(2011) Matthew D. Neal et al.   ANNALS OF SURGERY

Comparative Susceptibilities to Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence, and Failure from Patients in Two Phase III Trials of Fidaxomicin against Clostridium difficile Infection

(2011) Ellie J. C. Goldstein et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroActivities of CB-183,315, Vancomycin, and Metronidazole against 556 Strains of Clostridium difficile, 445 Other Intestinal Anaerobes, and 56 Enterobacteriaceae Species

(2011) Diane M. Citron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections

(2011) Kathleen M. Mullane et al.   CLINICAL INFECTIOUS DISEASES

Cumulative Antibiotic Exposures Over Time and the Risk of Clostridium difficile Infection

(2011) V. Stevens et al.   CLINICAL INFECTIOUS DISEASES

Systematic Review of Intestinal Microbiota Transplantation (Fecal Bacteriotherapy) for Recurrent Clostridium difficile Infection

(2011) Ethan Gough et al.   CLINICAL INFECTIOUS DISEASES

Complications of colonoscopy

(2011) Deborah A. Fisher et al.   GASTROINTESTINAL ENDOSCOPY

Comparison of the Burdens of Hospital-Onset, Healthcare Facility-Associated Clostridium difficile Infection and of Healthcare-Associated Infection due to Methicillin-Resistant Staphylococcus aureus in Community Hospitals

(2011) Becky A. Miller et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection

(2011) K. W. Garey et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fecal Microbiota Transplantation for Relapsing Clostridium difficile Infection in 26 Patients

(2011) Colleen R. Kelly et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Fidaxomicin versus Vancomycin forClostridium difficileInfection

(2011) Thomas J. Louie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rifaximin Is Effective for the Treatment ofClostridium difficile—Associated Diarrhea: Results of an Open-Label Pilot Study

(2011) David T. Rubin et al.   Gastroenterology Research and Practice

Tigecycline Exhibits Inhibitory Activity againstClostridium difficilein the Colon of Mice and Does Not Promote Growth or Toxin Production

(2010) Robin L. P. Jump et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Management ofClostridium difficileInfection: Thinking Inside and Outside the Box

(2010) Dale N. Gerding et al.   CLINICAL INFECTIOUS DISEASES

Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)

(2010) Stuart H. Cohen et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole

(2010) Ching-Lan Lu et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial

(2010) P. Patrick Basu et al.   Therapeutic Advances in Gastroenterology

Rifaximin Redux: Treatment of recurrent Clostridium difficile infections with Rifaximin immediately post-vancomycin treatment

(2009) Stuart Johnson et al.   ANAEROBE

Intravenous Tigecycline as Adjunctive or Alternative Therapy for Severe RefractoryClostridium difficileInfection

(2009) Bjorn L. Herpers et al.   CLINICAL INFECTIOUS DISEASES

Nitazoxanide versus Vancomycin inClostridium difficileInfection: A Randomized, Double‐Blind Study

(2009) Daniel M. Musher et al.   CLINICAL INFECTIOUS DISEASES

High Frequency of Rifampin Resistance Identified in an EpidemicClostridium difficileClone from a Large Teaching Hospital

(2009) Scott R. Curry et al.   CLINICAL INFECTIOUS DISEASES

Distinct ribotypes and rates of antimicrobial drug resistance in Clostridium difficile from Shanghai and Stockholm

(2009) H. Huang et al.   CLINICAL MICROBIOLOGY AND INFECTION

OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile Infection

(2008) T. J. Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin

(2008) R. O'Connor et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Emergence of reduced susceptibility to metronidazole in Clostridium difficile

(2008) S. D. Baines et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model

(2008) S. D. Baines et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Characterization of Clostridium difficile Strains Isolated from Patients in Ontario, Canada, from 2004 to 2006

(2008) H. Martin et al.   JOURNAL OF CLINICAL MICROBIOLOGY